Skip to main content
. 2024 Aug 24;14(8):e080862. doi: 10.1136/bmjopen-2023-080862

Table 2. Participant baseline characteristics by randomised treatment.

Placebo Triple Pill Overall Overall
Mean (SD) Mean (SD) Mean (SD) Median (range)
Number of participants 4 2 6 6
Female 2 1 3 3
Age, years 62.7 (6.4) 63.5 (9.9) 63.0 (6.7) 61.7 (56.5, 70.5)
Height, cm 166.5 (10.0) 165.0 (9.9) 166.0 (8.9) 168.5 (153.0, 175.0)
Weight, kg 89.5 (13.2) 66.5 (6.4) 81.8 (15.9) 80.5 (62.0, 105.0)
BMI 32.5 (5.5) 24.4 (0.6) 29.8 (6.0) 28.11 (24.0, 39.3)
Smoking
 Never smoker 2 1 3 3
 Ex-smoker 2 1 3 3
Alcohol, >1 per week 2 2 4 4
Highest level of education
 Undergraduate degree 1 1 2 2
 Postgraduate degree 2 1 3 3
 Other 1 1 1
Systolic BP 128.8 (7.4) 138.9 (1.6) 132.2 (7.8) 133.3 (121.7, 140.1)
Diastolic BP 83.1 (2.1) 87.9 (4.1) 84.7 (3.5) 84.4 (80.0, 90.8)
Heart rate 72.6 (3.2) 68.2 (NA) 71.7 (3.4) 72.7 (68.2, 76.2)
Glucose, mmol/L 5.3 (0.45) 5.0 (0.28) 5.2 (0.40) 5.2 (4.7, 5.7)
Total cholesterol, mmol/L 4.7 (1.04) 5.6 (0.57) 5.0 (0.97) 5.2 (3.2, 6.0)
LDL, mmol/L 2.75 (0.91) 2.90 (0.14) 2.8 (0.71) 2.9 (1.5, 3.6)
HDL, mmol/L 1.23 (0.34) 2.25 (0.35) 1.57 (0.61) 1.45 (0.90, 2.50)
Triglycerides, mmol/L 1.55 (0.40) 0.95 (0.21) 1.35 (0.45) 1.30 (0.80, 1.90)
Creatinine, µmmol/L 87.5 (22.5) 80.0 (14.1) 85.0 (19.0) 90.0 (55.0, 105.0)
Sodium, mmol/L 139.0 (2.9) 138.5 (2.1) 138.8 (2.5) 139.5 (135.0, 142.0)
Potassium, mmol/L 4.35 (0.39) 4.40 (0) 4.37 (0.30) 4.35 (4.00, 4.90)
BUN /urea, mmol/L 5.05 (1.41) 6.00 (0.99) 5.37 (1.27) 5.7 (3.6, 6.7)
eGRF, mL/min/1.73m2 70.3 (13.3) 81.5 (3.5) 74 (11.9) 72 (61, 90)
AST, IU/I 21.8 (5.5) 35.0 (1.4) 26.2 (8.1) 26 (17, 36)
ALT, IU/l 30.8 (14.8) 21 (0) 27.5 (12.5) 21.5 (16, 49)

ALTalanine transaminaseASTaspartate aminotransferaseBMIbody mass indexBPblood pressureBUNblood urea nitrogeneGFRestimated glomerular filtration rateHDLhigh-density lipoproteinLDLlow-density lipoprotein